Núria Cañete

Hospital Del Mar

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

J.A. Carrión

Pompeu Fabra University

Montserrat García–Retortillo

Hospital Del Mar

S. Coll

Hospital Del Mar

Marc Puigvehí

Hospital Del Mar

Teresa Broquetas

Hospital Del Mar

Felipe Bory

Hospital Del Mar

Helena Masnou

Hospital Universitari Germans Trias i Pujol

Joan Genescà

Universitat Autònoma de Barcelona

José Luís Calleja

Hospital Universitario Puerta de Hierro Majadahonda

José Castellote

Universitat de Barcelona

Cooperative Institutions

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

165

Universitat Autònoma de Barcelona

142

Universitat de Barcelona

128

Instituto de Salud Carlos III

123

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

104

Centro de Investigación Biomédica en Red

101

Hospital Clínic de Barcelona

Hospital Del Mar

Inserm

Hospital del Mar Research Institute

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients

AIDS (2010)

Eva Van den Eynde Juan Tiraboschi Cristina Tural Ricard Solà José Antonio López Mira

Objective: Guidelines recommendation to extend treatment duration in genotype 1 hepatitis C virus (HCV)/HIV-coinfected patients who clear the virus later than treatment week 4 is not evidence-based. Our main objective was to study the ability of week 12 viral response [early virologic response (EVR)] to predict long-term outcome in patients treated for 48 weeks. Design: Multicenter retrospective cohort analysis. Methods: Genotype 1 HCV treatment-naive, HIV-coinfected adult patients with compensated liver disease who started combination therapy with fixed-dose pegylated-interferon (pegIFN) alfa-2a or weight-based pegIFN alfa-2b plus ribavirin were included. Univariate and forward stepwise logistic regression analysis were used to identify predictors of sustained viral response (SVR) and relapse. Results: By intention-to-treat analysis, 31.3% (87/278) of patients achieved an SVR. SVR rate was more than three-fold higher in patients who cleared the virus by week 12 of treatment compared with late responders. Among 123 end-of-treatment responders, 36 (29.3%) relapsed. Relapse risk increased in patients with cirrhosis, in those with ribavirin dose reductions and in late responders: more than 65% of patients who cleared the virus between weeks 12 and 24 relapsed following 48 weeks of treatment compared with 10% of those attaining a complete EVR (<15 IU/ml) at treatment week 12 (risk ratio 6.4, 95% confidence interval 2.9–14.4). Conclusion: Viral response at treatment week 12 is a strong predictor of long-term outcome. Genotype 1 HCV/HIV-coinfected patients who achieve a complete EVR (<15 IU/ml) are at low risk of viral relapse after completing the standard 48 weeks of therapy.

Univariate analysis

Hepatitis C

10.1097/qad.0b013e3283350f7c

Cite

Citations (9)

Respiratory infection in patients with cirrhosis and acute varicealbleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients

Jorge Martínez Luís Téllez Virginia Hernández–Gea Bogdan Procopeț Álvaro Giráldez-Gallego

Source

Cite

Citations (0)

Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon

PLoS ONE (2016)

Martina Gambato Noelia Caro‐Pérez Patricia González Núria Cañete Zoe Mariñó

Real-life data showed an increased incidence of bacterial infections in patients with advanced liver disease receiving a protease inhibitor (PI)-containing antiviral regimen against hepatitis C (HCV). However, the causes of this event are unknown. We hypothesized that PIs might impair innate immune responses through the inhibition of proteases participating in the anti-bacterial functions of neutrophils and monocytes. The aims of the study were to assess phagocytic and oxidative burst capacity in neutrophils and monocytes obtained from patients receiving a PI containing-antiviral regimen, and to determine cytokine secretion after neutrophil stimulation with flagellin. Forty patients with chronic HCV (80% with cirrhosis) were enrolled in the study, 28 received triple therapy (Group A) with pegylated-interferon and ribavirin for 4 weeks followed by the addition of a PI (telaprevir, boceprevir or simeprevir), and 12 patients received an interferon-free regimen (Group B) with simeprevir and sofosbuvir. Phagocytosis and oxidative burst capacity were analyzed by flow cytometry at baseline, week 4, and week 8 of therapy. In neutrophils from Group A patients, oxidative burst rate and oxidative enzymatic activity per cell significantly decreased throughout the study period (p = 0.014 and p = 0.010, respectively). Pairwise comparisons showed a decrease between baseline and week 4 and 8 of therapy. No differences were observed after the introduction of the PI. The oxidative enzymatic activity per cell in monocytes significantly decrease during the study period (p = 0.042) due to a decrease from baseline to week 8 of therapy (p = 0.037) in patients from Group A. None of these findings were observed in Group B patients. Cytokine secretion did not significantly change during the study in both groups. In conclusion, our data suggest that the use interferon (rather than the PI) has a deleterious effect on neutrophil and monocyte phagocytic and oxidative burst capacity in this cohort of patients with HCV-related advanced liver fibrosis.

Simeprevir

Respiratory burst

Hepatitis C

Telaprevir

Boceprevir

Regimen

Pegylated interferon

10.1371/journal.pone.0166631

Cite

Citations (5)

Liver International (2023)

Ares Villagrasa Virginia Hernández–Gea Ramón Bataller Álvaro Giráldez Gallego Bogdan Procopeț

Abstract Background & Aims Alcohol‐related hepatitis (AH) encompasses a high mortality. AH might be a concomitant event in patients with acute variceal bleeding (AVB). The current study aimed to assess the prevalence of AH in patients with AVB and to compare the clinical outcomes of AH patients to other alcohol‐related liver disease (ALD) phenotypes and viral cirrhosis. Methods Multicentre, observational study including 916 patients with AVB falling under the next categories: AH ( n = 99), ALD cirrhosis actively drinking (d‐ALD) ( n = 285), ALD cirrhosis abstinent from alcohol (a‐ALD) ( n = 227) and viral cirrhosis ( n = 305). We used a Cox proportional hazards model to calculate adjusted hazard ratio (HR) of death adjusted by MELD. Results The prevalence of AH was 16% considering only ALD patients. AH patients exhibited more complications. Forty‐two days transplant‐free survival was worse among AH, but statistical differences were only observed between AH and d‐ALD groups (84 vs. 93%; p = 0.005), when adjusted by MELD no differences were observed between AH and the other groups. At one‐year, survival of AH patients (72.7%) was similar to the other groups; when adjusted by MELD mortality HR was better in AH compared to a‐ALD (0.48; 0.29–0.8, p = 0.004). Finally, active drinkers who remained abstinent presented better survival, independently of having AH. Conclusions Contrary to expected, AH patients with AVB present no worse one‐year survival than other patients with different alcohol‐related phenotypes or viral cirrhosis. Abstinence influences long‐term survival and could explain these counterintuitive results.

Liver disease

Alcoholic Hepatitis

10.1111/liv.15606

Cite

Citations (6)

801 LONG-TERM EVOLUTION OF LIVER FIBROSIS IN MILD–MODERATE CHRONIC HEPATITIS C: STUDY WITH PAIRED BIOPSIES

Journal of Hepatology (2013)

Núria Cañete Miguel López Isabel Ojanguren Isabel Cirera Montserrat García–Retortillo

10.1016/s0168-8278(13)60803-x

Cite

Citations (0)

Survival in patients with chronic hepatitis C and mild-moderate fibrosis according to antiviral treatment response

Journal of Hepatology (2017)

Marc Puigvehí S. Coll A. Raga Alessandra Soriano Núria Cañete

Antiviral Treatment

Hepatitis C

10.1016/s0168-8278(17)31385-5

Cite

Citations (0)

SAT-267 The interaction between metabolic syndrome and alcohol consumption after an episode of alcohol-associated hepatitis is associated with increased mortality: results from de spanish registry of alcohol-associated liver disease (REHALC)

Journal of Hepatology (2024)

Jordi Gratacós‐Ginès María Del Barrio Pilar Ruz-Zafra Miriam Celada-Sendino Ares Villagrasa

Liver disease

Alcoholic Hepatitis

Alcohol and health

10.1016/s0168-8278(24)00710-4

Cite

Citations (0)

Congenital Disorders and Anatomical Variations of the Thoracic Aorta.

J. Cambronero Gómez G. Sánchez Núñez Pedro Ortuño Muro Núria Cañete Gerard Carbo

Poster: ECR 2015 / C-2219 / Congenital Disorders and Anatomical Variations of the Thoracic Aorta. by: J. Cambronero Gomez 1, G. Sanchez Nunez1, P. Ortuno Muro2, N. Canete3, G. Carbo1, V. Cuba Camasca1; 1Girona/ES, 2Sant Cugat del Valles/ES, 3Mataro/ES

Thoracic aorta

Source

Cite

Citations (0)

Use of rifaximin in alcoholic hepatitis: Pilot study

Journal of Hepatology (2018)

César Jiménez Maria Teresa Ventura María Sala Núria Cañete María A. Poca

Rifaximin

Alcoholic Hepatitis

10.1016/s0168-8278(18)31905-6

Cite

Citations (4)

Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding

Alimentary Pharmacology & Therapeutics (2008)

Javier P. Gisbert Xavier Calvet Faust Feu Felipe Bory Ángel Cosme

Sirs, We read with interest the article by Manuel et al.1 examining whether the decreased prevalence of Helicobacter pylori and increased use of eradication regimens have affected the prevalence of peptic ulcer (PU)-related hospitalizations. The authors conducted a retrospective analysis of hospital discharges of PU patients in the US over the last decade, and concluded that, despite a decreasing prevalence of H. pylori and the increasing use of successful H. pylori eradication regimens, the prevalence of PU and its complications (mainly upper gastrointestinal haemorrhage) have not changed. The authors suggest that, in the US, other aetiologies, including nonsteroidal anti-inflammatory drugs (NSAIDs), may be playing a larger role than once thought. Recently, we evaluated the effect of H. pylori eradication on ulcer bleeding recurrence in a prospective, long-term study including 422 patients with a total of 906 patient-years of follow-up and concluded that PU rebleeding does not occur in patients with complicated ulcers after H. pylori eradication.2 We have just updated the results of this study, now including 565 patients with PU bleeding (70% duodenal ulcer, 25% gastric ulcer, and 5% pyloric ulcer) followed up for at least 12 months (with a total of 1465 patient-years of follow-up). Several eradication therapies were used (patients with therapy failure received a second or third course). Eradication was confirmed by 13C-urea breath test, and patients with eradication success did not receive maintenance anti-ulcer therapy. Recurrence of bleeding occurred in three patients, giving an incidence as low as 0.2% per patient-year of follow-up. Rebleeding was demonstrated in two patients at 1 year (which occurred after NSAID use in both cases), and in one patient at 2 years (which occurred after H. pylori reinfection). These results indicate, in accordance with the suggestion by Manuel et al.,1 that although PU rebleeding may not occur in patients with complicated ulcers after H. pylori eradication, NSAID intake (or H. pylori reinfection) may cause rebleeding in H. pylori-eradicated patients. Personal and funding interests: None.

Urea breath test

Spirillaceae

Peptic

10.1111/j.1365-2036.2008.03737.x

Cite

Citations (3)